PEDRO PEREIRA NEFFA
Índice h a partir de 2011
2
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
8 resultados
Resultados de Busca
Agora exibindo 1 - 8 de 8
conferenceObject Surveillance Functional Imaging Has Limited Role in Solitary Plasmacytomas: International Multi-Centre Study of Clinical Outcomes(2017) SHARPLEY, Faye A.; NEFFA, Pedro; PANITSAS, Fotis; KOTHARI, Jaimal; CUTTER, David; SZOR, Roberta Shcolnik; SUBESINGHE, Manil; MARTINEZ, Gracia; ROCHA, Vanderson; RAMASAMY, KarthikconferenceObject Treating multiple myeloma in a resource-limited setting: real-world outcomes(2022) MATINEZ, Gracia; SEGURO, Fernanda; JACOMASSI, Mayara; VISNADI, Helena; ATANAZIO, Marcelo; SZOR, Roberta; NEFFA, Pedro; PEREIRA, Thales; SILVA, Wellington; DORLHIAC, Pedro; VELASQUES, Rodrigo; BASSOLI, Lucas; ROCHA, VandersonconferenceObject Lung Infiltrates Secondary To Dengue Fever: Case Report(2017) ATHAYDE, R. B. De; OLIVEIRA FILHO, J. B.; PILOTO, B. M.; TARTAGLIA, R. S.; MIRANDA, R. R.; ENDLICH, B. N.; NEFFA, P. P.; COSTA, A. N.- Safety and Feasibility Analysis of a Prospective Trial on Stereotactic Body Radiotherapy for Solitary Bone Plasmacytoma(2021) MAURO, Geovanne Pedro; NEFFA, Pedro Pereira; VILLAR, Rosangela Correa; MARTINEZ, Gracia Aparecida; CARVALHO, Heloisa de AndradeBackground: There have been reports on the use of hypofractionated stereotactic body radiotherapy (SBRT) for bone plasmacytomas, but no prospective data are available. We present the initial analysis of an ongoing prospective protocol on SBRT addressing the feasibility and safety of this treatment for solitary bone plasmacytomas. Patients and Methods: A prospective cohort of SBRT for solitary bone plasmacytoma was developed. Patients could receive different doses depending on the index bone, from single fraction for skull base lesions, 24 Gy in 3 fractions for spine lesions, and 30 Gy in 5 fractions for other bones. Overall survival, bone events, local control, and progression to multiple myeloma (MM) were measured and compared to our retrospective cohort of patients treated with conformal standard-dose radiotherapy. Quality of life was assessed via the EORTC QLQ-C30 questionnaire, and toxicities were assessed by the CTCAE v5.0 criteria. After 1 year or the inclusion of 5-10 patients, a feasibility and safety analysis was programmed. Results: Between April 2018 and April 2019, 5 patients were included. All were male, with a median age of 53.1 years. The median follow-up was 21.8 months. No patient had local progression, bone event, or died. Two patients had progressions to MM. The mean survival free of progression to MM was 18.6 months, compared to 19 months in the retrospective cohort; median values were not reached. There were no grade 3 toxicities. Conclusion: SBRT for plasmacytoma is safe and feasible. More robust data are awaited.
- Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era(2019) SHARPLEY, F. A.; NEFFA, P.; PANITSAS, F.; KOTHARI, J.; SUBESINGHE, M.; CUTTER, D.; SZOR, R. Shcolnik; MARTINEZ, G. Aparedcida; ROCHA, V; RAMASAMY, K.Background The risk of recurrence of solitary plasmacytoma (SP)/progression to MM is well established, but patient, imaging and treatment factors influencing risk of progression require further evaluation. Methods This is a retrospective analysis of 66 SP patients (23 UK, 43 Brazil) diagnosed 1989-2016. Patient baseline characteristics were recorded. The incidence of progression to MM was calculated, including biochemical and imaging findings and the treatment modality received. Survival estimates were determined by Kaplan-Meier analyses. Results With a median follow-up of 53.6 months the 5 year overall survival (OS) was 90.7% (95%CI 79-96%). The median progression free survival (PFS) from diagnosis was 61 months. Cumulative incidence of progression to MM was 49.9% at 5 years (95% CI 35.6-62.6%) and was significantly higher with bone plasmacytoma (47.2%, 95%CI 31.9-61.1%), than an extramedullary location (8.3%, 95%CI 0.4-32.3%, Gray test p = 0.0095)). The majority of patients with solitary bony plasmacytoma (SBP) received radiotherapy (RT) (51/53, 96.2%) whereas most extramedullary cases were treated with surgical resection (7/13, 53.8%). A small proportion of SBP patients received additional upfront chemotherapy, with 5/6 in remission after a median follow-up (FU) of 10 years. The diagnostic yield of surveillance functional FU imaging without other indications of relapse/progression was low. The positive predictive value of functional FU imaging was high but with a low negative predictive value, especially in cases of suspected relapse/progression. Conclusion Our data suggests functional imaging should be used if clinical suspicion of relapse/progression, rather than a routine surveillance tool, and upfront adjuvant chemotherapy is worthy of prospective evaluation.
- Impact of bone events on survival in solitary bone plasmacytoma(2020) MAURO, Geovanne Pedro; NEFFA, Pedro Pereira; VILLAR, Rosangela Correa; MARTINEZ, Gracia Aparecida; CARVALHO, Helois de AmdradeBackground: Although much studied in multiple myeloma, bone events (BE) can also cause important morbidity in bone plasmacytoma patients. To our knowledge, the effect of BE on overall survival (OS) and progression to multiple myeloma free-survival (MPFS) also has never been studied. Patients and Methods: Fifty-nine patients treated from 2008 to 2017 were retrospectively assessed. All patients had histological proof of disease and were treated with radical radiotherapy (RT). Available clinical information for at least 6 months follow-up or until death had to be available. BE were described as one of the following events in the index bone: fractures, osteomyelitis, chronic pain, surgery or loss of limb function after RT. Results: Mean age at diagnosis was 57.3 years (18-80); most male (67.8%). Mean OS, bone event free-survival (BEFS), local progression-free survival (LPFS) and MPFS were 41, 36, 37 and 19 months, respectively. There were 15 deaths. BEFS (p = 0.008) and age>55y (p = 0.044) were associated with MPFS. Only BEFS correlated with OS (p = 0.029). BE was independently associated with both MPFS and OS in multivariate analysis. Conclusion: BE and survival end-points were correlated. BE should be investigated in prospective trials.
- Bone Event: A New Surrogate to Solitary Plasmacytoma(2018) MAURO, G. P.; CARVALHO, H. D. A.; NEFFA, P.; MARTINEZ, G. A.; VILLAR, R. C.
- Disseminated Skin Lesions After Allogeneic Hematopietic Stem Cell Transplantation(2018) NEFFA, Pedro Pereira; SCHMIDT FILHO, Jayr; RAMOS, Jessica Fernandes; OKAY, Thelma Suely; CASTELLI, Jussara Bianchi; ROCHA, Vanderson; COSTA, Silvia Fiqueiredo; BATISTA, Marjorie Vieira